SOPHIA: Second Interim OS Analysis of Margetuximab + CT vs Trastuzumab + CT for HER2+ MBC After Previous HER2 Therapy

December 10-14, 2019; San Antonio, Texas
In patients with HER2+ metatstatic breast cancer after prior anti-HER2 therapy, margetuximab + chemotherapy continues to provide PFS benefit vs trastuzumab + chemotherapy with similar OS benefit in the second interim survival analysis of SOPHIA.
Format: Microsoft PowerPoint (.ppt)
File Size: 254 KB
Released: December 20, 2019


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Merck Sharp & Dohme Corp.
Puma Biotechnology
Seattle Genetics

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Interactive online tool with strategies to assess and manage AEs associated with oral targeted therapy for HR+, HER2– breast cancer, from Clinical Care Options

Donna M. Fitzgerald, PA-C, MPAS Matthew P. Goetz, MD Marissa Marti, APRN, AGNP-C, AOCNP Joyce O'Shaughnessy, MD Laura M. Spring, MD Released: September 14, 2021

Downloadable slideset with the latest expert insights on CDK4/6 inhibitors for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: August 24, 2021

Key takeaways from international and US experts on CDK4/6 inhibitors for HR+/HER2- early breast cancer, from Clinical Care Options (CCO)

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: August 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.